Migalastat
Brand names: Galafold · Active ingredient: Migalastat Hydrochloride
In short: GALAFOLD is indicated for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene (GLA) variant based on in vitro assay data . This indication is approved under accelerated approval based on reduction in kidney interstitial capillary cell globotri
What is Migalastat used for?
GALAFOLD is indicated for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene (GLA) variant based on in vitro assay data .
This indication is approved under accelerated approval based on reduction in kidney interstitial capillary cell globotriaosylceramide (KIC GL-3) substrate . Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.
Migalastat dosage
Select adults with confirmed Fabry disease who have an amenable GLA variant for treatment with GALAFOLD .
Treatment is indicated for patients with an amenable GLA variant that is interpreted by a clinical genetics professional as causing Fabry disease (pathogenic, likely pathogenic) in the clinical context of the patient. Consultation with a clinical genetics professional is strongly recommended in cases where the amenable GLA variant is of uncertain clinical significance (VUS, variant of uncertain significance) or may be benign (not causing Fabry disease).
The recommended dosage of GALAFOLD is 123 mg orally once every other day.
Take GALAFOLD at the same time of day and do not take on consecutive days.
Swallow capsule whole. Do not cut, crush, or chew the capsule.
Take GALAFOLD on an empty stomach. Do not consume food or caffeine at least 2 hours prior to and 2 hours after taking GALAFOLD to give a minimum 4 hour fast .
Water (plain, flavored, or sweetened), fruit juices without pulp, and caffeine-free carbonated beverages can be consumed during the fasting period.
If the GALAFOLD dose is missed, take the missed dose if it is within 12 hours of the time that the dose should have been taken. If more than 12 hours have passed, take GALAFOLD at the next planned dosing day and time following the original every-other-day dosing schedule.
How to take Migalastat — instructions & advice from the label
Advise the patient to read the FDA‑approved patient labeling (Patient Information and Instructions for Use).
Administration
Advise the patient:
To take GALAFOLD once every other day at the same time of day and do not take on consecutive days .
Swallow capsule whole. Do not cut, crush, or chew the capsule .
Take GALAFOLD on an empty stomach. Do not consume food or caffeine at least 2 hours prior to and 2 hours after taking GALAFOLD to give a minimum 4 hour fast .
Water (plain, flavored, or sweetened), fruit juices without pulp, and caffeine‑free carbonated beverages can be consumed during the fasting period .
If the GALAFOLD dose is missed, take the missed dose if it is within 12 hours of the time that the dose should have been taken. If more than 12 hours have passed, take GALAFOLD at the next planned dosing day and time following the original every‑other‑day dosing schedule .
To inform the healthcare provider of all medicines the patient takes, including prescription and over‑the‑counter medicines, vitamins, and herbal supplements . …
Warnings & precautions
Do not take this medicine if: None.
Migalastat side effects
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
In clinical trials, 139 patients with Fabry disease (79 females, 60 males, 92% Caucasian, ages 16 to 72 years), who were naĂŻve to GALAFOLD or previously treated with enzyme replacement therapy, were exposed to at least one dose of GALAFOLD. Of the 139 patients, 127 patients were exposed to GALAFOLD 123 mg every other day for 6 months and 123 patients were exposed for greater than one year. The clinical trials included one randomized, double-blind, placebo-controlled clinical trial of 6 months duration followed by a 6-month open-label treatment phase (Study 1) . A second trial was a randomized, open-label, active-controlled clinical trial of 18 months duration in patients with Fabry disease receiving enzyme replacement therapy who were randomized to either switch to GALAFOLD or continue enzyme replacement therapy (Study 2; NCT01218659). In addition, there were two open-label, long-term extension trials.
The most common adverse reactions reported with GALAFOLD (≥ 10%) during the 6-month placebo-controlled, double-blind phase of Study 1 were headache, nasopharyngitis, urinary tract infection, nausea, and pyrexia. …
Drug interactions
Co-administration of GALAFOLD with caffeine decreases migalastat AUC and Cmax
which may reduce GALAFOLD efficacy. Avoid co-administration of GALAFOLD with caffeine at least 2 hours before and 2 hours after taking GALAFOLD .
About this medicine
Migalastat, an alpha-galactosidase A (alpha-Gal A) pharmacological chaperone, is a low molecular weight iminosugar and an analogue of the terminal galactose of globotriaosylceramide (GL-3).
Migalastat is present in the form of a hydrochloride salt in GALAFOLD. The chemical name for migalastat hydrochloride is (+)-(2R,3S,4R,5S)-2-(hydroxymethyl) piperidine-3,4,5-triol hydrochloride. Its molecular formula is C6H13NO4•HCl, molecular mass is 199.63 g/mol, and its chemical structure is depicted below.
Migalastat hydrochloride is a white to almost white crystalline solid. It is freely soluble in aqueous media within the pH range of 1.2 to 7.5.
GALAFOLD (migalastat) capsules for oral administration contain 123 mg of migalastat (equivalent to 150 mg migalastat hydrochloride) as a white to pale brown powder and are supplied in a size “2” hard gelatin capsule with an opaque blue cap and an opaque white body imprinted with “A1001” in black ink. The inactive ingredients are magnesium stearate and pregelatinized starch. …
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 66dbd928-0f1c-48b1-a832-54e4abd9f1db. Read the full official label on DailyMed.